Patent · US Revoked

Molecules with specificity for CD45 and CD79

US10730952B2 · kind B2 · utility

0Cited by
40References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 16, 2015
Grant dateAug 4, 2020
Priority date
Expiry dateJul 16, 2035

Classification

  • Technology area (CPC —)General

Abstract

The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.